Wigen biomedicine technology (Shanghai)Co., Ltd established in April 2018 is a high-tech biomedical company for developing innovative drugs and technologies. We focus on designing and developing anti-cancer drugs, and also start to expand to other therapeutic areas including immunity and metabolism. Harnessing our expertise in small molecule drug discovery, we have developed technical capabilities and platforms for target identification, covalent/allosteric small molecule inhibitors, lysine targeting technology, PROTAC, as well as drug conjugation including ADC.

Our research team comprises of more than 50 people with experiences in multiple disciplines across drug discovery, including 9 people with doctorate degrees. In addition, we employed 30 FTEs from reputable CROs to support internal research.

Within 4 years, we have made key progresses in drug discovery and technology platform establishment. More than 80 invention patents have been applied, 9 of which have been authorized, and a total of 25 research projects are in progress.6 products from our pipeline have entered into phase I clinical trials. In addition, 5 more have entered IND-enabling studies. In the future, we will keep advancing 2-4 products into clinical trial every year.

• 2018

  Year We Established

• 80

  Patents  Applied

• 6

  Clinical Products